Globus Medical, Inc. $GMED Shares Purchased by Clearline Capital LP

Key Points

• Institutional investors sharply increased exposure to Globus Medical: Clearline Capital LP lifted its stake by 342.5% to 148,472 shares (~$8.5M), Antipodes Partners now holds 891,043 shares (~$51M), and institutions own about 95.16% of the stock.
• Corporate insiders have been net sellers recently: Director Leslie Norwalk and CFO Kyle Kline sold shares on January 8, and insiders sold 35,594 shares (~$3.33M) in the last 90 days while retaining 18.51% ownership.
• Fundamental and analyst momentum is positive: Globus topped quarterly estimates with $1.28 EPS and $826.4M revenue (up 25.7% YoY), prompting multiple price-target upgrades and an aggregate MarketBeat consensus of "Moderate Buy" with an average target of $104.36.

Clearline Capital LP lifted its holdings in Globus Medical, Inc. (NYSE:GMED - Free Report) by 342.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 148,472 shares of the medical device company's stock after purchasing an additional 114,917 shares during the period. Clearline Capital LP owned about 0.11% of Globus Medical worth $8,503,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. ANTIPODES PARTNERS Ltd increased its position in shares of Globus Medical by 49,020.3% in the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company's stock valued at $51,034,000 after buying an additional 889,229 shares in the last quarter. Paradice Investment Management LLC lifted its position in shares of Globus Medical by 20.9% during the 3rd quarter. Paradice Investment Management LLC now owns 663,038 shares of the medical device company's stock valued at $37,972,000 after buying an additional 114,433 shares in the last quarter. Foresight Group Ltd Liability Partnership grew its stake in Globus Medical by 160.7% in the 3rd quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company's stock valued at $24,142,000 after acquiring an additional 259,870 shares during the period. William Blair Investment Management LLC grew its stake in Globus Medical by 17.2% in the 3rd quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company's stock valued at $161,454,000 after acquiring an additional 414,134 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in Globus Medical by 189.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 476,531 shares of the medical device company's stock worth $27,953,000 after acquiring an additional 312,149 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company's stock.

Insiders Place Their Bets

In related news, Director Leslie V. Norwalk sold 2,000 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the sale, the director owned 10,419 shares of the company's stock, valued at approximately $1,053,360.90. This trade represents a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Kyle Kline sold 3,594 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $101.10, for a total value of $363,353.40. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 35,594 shares of company stock valued at $3,332,253 in the last ninety days. 18.51% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on GMED shares. Piper Sandler restated an "overweight" rating and set a $115.00 price objective (up from $90.00) on shares of Globus Medical in a research report on Thursday, January 8th. Needham & Company LLC lifted their target price on shares of Globus Medical from $112.00 to $114.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Wells Fargo & Company boosted their target price on shares of Globus Medical from $98.00 to $104.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Barclays upped their price target on shares of Globus Medical from $118.00 to $123.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 25th. Finally, Canaccord Genuity Group raised their price target on shares of Globus Medical from $105.00 to $112.00 and gave the company a "buy" rating in a research note on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Globus Medical has an average rating of "Moderate Buy" and an average price target of $104.36.

Key Stories Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a "Strong‑Buy" rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average "Moderate Buy" rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of "Moderate Buy" by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Globus Medical Stock Up 0.4%

Shares of NYSE GMED opened at $84.81 on Friday. The firm has a 50-day simple moving average of $90.71 and a 200-day simple moving average of $78.37. The stock has a market capitalization of $11.47 billion, a price-to-earnings ratio of 21.52, a price-to-earnings-growth ratio of 1.99 and a beta of 1.05. Globus Medical, Inc. has a 52 week low of $51.79 and a 52 week high of $101.40.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share for the quarter, topping analysts' consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The firm had revenue of $826.42 million for the quarter, compared to analyst estimates of $803.29 million. During the same period in the previous year, the business posted $0.84 earnings per share. Globus Medical's quarterly revenue was up 25.7% on a year-over-year basis. As a group, equities research analysts expect that Globus Medical, Inc. will post 3.44 EPS for the current year.

Globus Medical Company Profile

Globus Medical, Inc NYSE: GMED is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.